Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab for persistent redness and flushing in rosacea
2019-003971-20Phase 2Completed
- Sponsor
- Rigshospitalet Glostrup
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erenumab in Erythematotelangiectatic Rosacea (ETR), sponsored by Rigshospitalet Glostrup. Primary endpoint: Mean change in days with moderate to extreme flushing. Started Dec 2019; status: completed.
02
Drugs
erenumab
03
Conditions
Erythematotelangiectatic Rosacea (ETR)
Beyond the preview
Go deeper on 2019-003971-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003971-20.